Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response

BACKGROUND: The oncogenic PI3K/Akt/mTOR pathway is frequently activated in HCC. Data on the mTOR inhibitor, temsirolimus, is limited in HCC patients with concomitant chronic liver disease. The objectives of this study were: (1) In phase I, to determine DLTs and MTD of temsirolimus in HCC patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Yeo, Winnie, Chan, Stephen L, Mo, Frankie KF, Chu, Cheuk M, Hui, Joyce WY, Tong, Joanne HM, Chan, Anthony WH, Koh, Jane, Hui, Edwin P, Loong, Herbert, Lee, Kirsty, Li, Leung, Ma, Brigette, To, Ka F, Yu, Simon CH
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4434865/
https://www.ncbi.nlm.nih.gov/pubmed/25962426
http://dx.doi.org/10.1186/s12885-015-1334-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4434865/
https://www.ncbi.nlm.nih.gov/pubmed/25962426
http://dx.doi.org/10.1186/s12885-015-1334-6

Ejemplares similares